

AMENDMENTS TO THE CLAIMS

The listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently amended) An antibody or antibody fragment which specifically binds an isolated mammalian protein having anti-angiogenic activity and that is a receptor for an N-terminal fragment of plasminogen comprising kringle domains 1-4 and/or 5 wherein said protein does not cleave plasminogen kringle domains and wherein said protein comprises an amino acid sequence having 80% sequence homology or greater to SEQ ID NO: 4 or SEQ ID NO:2.

2. (Currently amended) The antibody or antibody fragment according to claim 1, wherein said protein comprises an amino acid sequence wherein said sequence has 80% sequence homology or greater to SEQ ID No: 4 ~~or~~ and has sequence homology equal to or greater than 80% to SEQ ID Nos:2.

3. (Previously presented) The antibody or antibody fragment according to claim 2, wherein said protein comprises the amino acid sequence of SEQ ID NO. 2.

4. (Canceled) The antibody or antibody fragment according to claim 2, wherein said protein comprises the amino acid sequence of SEQ ID NO. 3, and wherein the amino acid residue in position 135 is Asn, Ser or Asp and the three amino acid residues in positions 148 to 150 are the tripeptide Glu-Leu-Ala or the tripeptide Thr-Trp-Pro.

5. (Previously presented) The antibody or antibody fragment according to claim 1, wherein said protein comprises the amino acid sequence of SEQ ID NO.4.

6. (Previously presented) An antibody or antibody fragment to a peptide capable of binding an N-terminal fragment of plasminogen and which has an amino acid sequence comprising at least 10 contiguous amino acid residues of SEQ ID NO.2.

7. (Previously presented) The antibody according to claim 1 which is a monoclonal antibody or fragment thereof.

8. (Previously presented) The antibody according to claim 2 which is a monoclonal antibody or fragment thereof.

9. (Previously presented) The antibody according to claim 3 which is a monoclonal antibody or fragment thereof.

10. (Previously presented) The antibody according to claim 4 which is a monoclonal antibody or fragment thereof.

11. (Previously presented) The antibody according to claim 5 which is a monoclonal antibody or fragment thereof.

12. (Canceled) The antibody according to claim 6 which is a monoclonal antibody or fragment thereof.

13. (Previously presented) A recombinant cell expressing the antibody according to claim 1.

14. (Previously presented) A recombinant cell expressing the antibody according to claim 2.

15. (Previously presented) A recombinant cell expressing the antibody according to claim 3.

16. (Previously presented) A recombinant cell expressing the antibody according to claim 4.
17. (Previously presented) A recombinant cell expressing the antibody according to claim 5.
18. (Canceled) A recombinant cell expressing the antibody according to claim 6.
19. (New) A composition comprising an antibody according to any one of claims 1-3 and 5-11 together with a pharmaceutically acceptable carrier.
20. (New) A method for treating an angiogenesis related disease or disorder comprising administering an effective amount of an antibody of any one of claims 1-3 and 5-11 to a patient in need thereof.